Diagnostic Characterization and Evolution of "Triple Negative" Thrombocytosis (CASTETTE)
Evaluation of Event free survival in patients with triple-negative thrombocytosis
Myeloproliferative Neoplasm
Event-free survival, 3 years
Patients with non-reactive thrombocytosis, explored at least by bone marrow biopsy and NGS panel will be included. Clinical and biological characteristics as well as evolution will be recorded retrospectively.